China Pharma Holdings, Inc. (CPHI)
NYSEAMERICAN: CPHI · Real-Time Price · USD
1.606
+0.102 (6.78%)
At close: Nov 6, 2025, 4:00 PM EST
1.606
0.00 (0.00%)
After-hours: Nov 6, 2025, 6:30 PM EST
China Pharma Holdings Revenue
China Pharma Holdings had revenue of $1.03M in the quarter ending June 30, 2025, with 10.90% growth. This brings the company's revenue in the last twelve months to $4.40M, down -29.64% year-over-year. In the year 2024, China Pharma Holdings had annual revenue of $4.53M, down -35.41%.
Revenue (ttm)
$4.40M
Revenue Growth
-29.64%
P/S Ratio
0.90
Revenue / Employee
$19,626
Employees
224
Market Cap
5.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.53M | -2.48M | -35.41% |
| Dec 31, 2023 | 7.01M | -1.09M | -13.48% |
| Dec 31, 2022 | 8.10M | -1.54M | -15.95% |
| Dec 31, 2021 | 9.64M | -1.22M | -11.27% |
| Dec 31, 2020 | 10.87M | -57.49K | -0.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CPHI News
- 7 months ago - China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split - PRNewsWire
- 11 months ago - China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville - PRNewsWire
- 11 months ago - China Pharma Announces the Entry of "At-The-Market" Equity Offering - PRNewsWire
- 1 year ago - China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 - PRNewsWire
- 1 year ago - China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split - PRNewsWire
- 2 years ago - China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device - PRNewsWire
- 2 years ago - China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs - PRNewsWire
- 3 years ago - China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask - PRNewsWire